The Impact of Off-Patent Drug Acquisitions on Prices
Gupta R, Henkel A, Forman HP, Ross JS. The Impact of Off-Patent Drug Acquisitions on Prices. Journal Of General Internal Medicine 2018, 33: 1007-1009. PMID: 29687433, PMCID: PMC6025665, DOI: 10.1007/s11606-018-4372-3.Peer-Reviewed Original ResearchAffordability and availability of off-patent drugs in the United States—the case for importing from abroad: observational study
Gupta R, Bollyky TJ, Cohen M, Ross JS, Kesselheim AS. Affordability and availability of off-patent drugs in the United States—the case for importing from abroad: observational study. The BMJ 2018, 360: k831. PMID: 29555641, PMCID: PMC5858606, DOI: 10.1136/bmj.k831.Peer-Reviewed Original ResearchConceptsOff-patent drugsObservational studyRare diseasePrescription drugsPatent drugsStudy drugTotal Medicaid spendingCardiovascular diseaseOrphan drug designationPsychiatric diseasesDrug AdministrationPatient accessInfectious diseasesDiseaseDrug characteristicsEssential medicinesDrugsGeneric versionsGeneric drugsMedicaid spendingNovel tabletRegulatory agenciesFDAUnited StatesTreatment areaPediatric Exclusivity and Regulatory Authority: Implications of Amgen v HHS
Kim J, Ross JS, Kapczynski A. Pediatric Exclusivity and Regulatory Authority: Implications of Amgen v HHS. JAMA 2018, 319: 21-22. PMID: 29117365, DOI: 10.1001/jama.2017.16477.Commentaries, Editorials and Letters